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ABSTRACT: A safer treatment for toxoplasmosis would be
achieved by improving the selectivity and potency of
dihydrofolate reductase (DHFR) inhibitors, such as pyrimethamine (1), for Toxoplasma gondii DHFR (TgDHFR) relative
to human DHFR (hDHFR). We previously reported on the
identiﬁcation of meta-biphenyl analog 2, designed by in silico
modeling of key diﬀerences in the binding pocket between
TgDHFR and hDHFR. Compound 2 improves TgDHFR
selectivity 6.6-fold and potency 16-fold relative to 1. Here, we
report on the optimization and structure−activity relationships of this arylpiperazine series leading to the discovery of 5(4-(3-(2-methoxypyrimidin-5-yl)phenyl)piperazin-1-yl)pyrimidine-2,4-diamine 3. Compound 3 has a TgDHFR IC50 of 1.57 ±
0.11 nM and a hDHFR to TgDHFR selectivity ratio of 196, making it 89-fold more potent and 16-fold more selective than 1.
Compound 3 was highly eﬀective in control of acute infection by highly virulent strains of T. gondii in the murine model, and it
possesses the best combination of selectivity, potency, and prerequisite drug-like properties to advance into IND-enabling,
preclinical development.

■

The recommended ﬁrst-line treatment for toxoplasmosis is a
combination therapy based on pyrimethamine (1) and
sulfadiazine, supplemented with leucovorin (also known as
folinic acid) to protect against bone marrow suppression.8
Pyrimethamine and sulfadiazine act synergistically on the folate
metabolic pathway thereby inhibiting T. gondii proliferation
and survival.9,10 The drugs inhibit DHFR and dihydropteroate
synthase (DHPS), respectively, and consequently block the
synthesis of tetrahydrofolate, a key cofactor for thymidylate
synthase. Thymidylate synthase is a methyl transferase that
produces deoxythymidine monophosphate from deoxyuridine
monophosphate. In many organisms including T. gondii and
humans, this pathway is the only means by which thymidine
can be supplied, making it essential for DNA synthesis and
cellular proliferation.10,11 Importantly, although the combination of pyrimethamine and sulfadiazine can control actively
proliferating forms such as tachyzoites, these agents have little
eﬀect on the semidormant bradyzoite stages within tissue cysts
and hence do not cure infection.12

INTRODUCTION

Toxoplasmosis is caused by the protozoan parasite Toxoplasma
gondii (T. gondii), an obligate intracellular parasite capable of
infecting a wide range of hosts and many diﬀerent types of
cells.1 Approximately one-third of the population worldwide is
chronically infected with various strains of T. gondii.2
Infections occur through consuming contaminated food or
water and mother-to-child (congenital/vertical) and iatrogenic
(transplanted organs and blood transfusion) transmission.3
The parasitic infection is kept in check by the immune system
where it exists in a latent bradyzoite form contained within
tissue cysts that are commonly found in skeletal muscle and
the central nervous system (CNS).4 However, in cases where
the immune system is compromised, such as in a developing
fetus or in patients with HIV, undergoing cancer chemotherapy
or immunosuppressive treatment for organ transplantation, the
parasite can transition to an active, fast replicating, and tissue
damaging tachyzoite form.5 Depending upon localization of
the tachyzoites, active infection can cause, among other
conditions, myocarditis, blindness, and encephalitis and is
associated with a high mortality rate for HIV patients, even for
those on active antiretroviral treatment.5−8
© 2019 American Chemical Society
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Adverse events associated with pyrimethamine-based
therapy in toxoplasmosis often result in a need to reduce
dosing or discontinue therapy.13 The adverse events are mainly
mechanism-based related to inhibition of folic acid metabolism
in host tissues with high metabolic activity (e.g., epithelium
and bone marrow).14 In mice, pyrimethamine has only about a
3-fold safety multiple between minimal eﬀective dose and
maximum tolerated dose.15 Leucovorin, a form of tetrahydrofolate that is selectively taken up by human cells, is often
coadministered to help alleviate the impact of mechanismbased toxicity to the host.16−19 The use of pyrimethamine is
also not suitable during the ﬁrst trimester of pregnancy owing
to its inhibition of human DHFR which can impact fetal
organogenesis.19 In addition, about 3% of the general
population and 30% of patients with HIV/AIDS have a
hypersensitivity reaction to the sulfonamide component of the
treatment regimen.20−22 Therefore, ﬁnding a standalone
treatment would be of signiﬁcant beneﬁt to the HIV patient
population most at risk of toxoplasmosis encephalitis and sulfa
hypersensitivities. Finally, high doses of pyrimethamine can
induce seizures, a likely consequence of oﬀ-target pharmacology.23 The adverse events associated with pyrimethamine and
sulfadiazine therapy could be reduced or eliminated by
selectively inhibiting only the parasite DHFR. There have
been numerous attempts to discover more selective inhibitors
of TgDHFR but with limited success.24−28 Recently, the crystal
structure of TgDHFR was solved.29 This ﬁnding has enabled
comparative modeling between the human and T. gondii
enzymes, leading to the design and discovery of more selective
TgDHFR small molecules such as TRC-19 (2).30
Ideally, a next generation TgDHFR inhibitor would have
suﬃcient selectivity so that maximal parasiticidal activity would
occur without concomitant inhibition of human hDHFR.
Therefore, we hypothesized it would be important that the
compound exhibit TgDHFR to hDHFR selectivity of at least
150-fold, which is about 10-fold greater than that of
pyrimethamine, and possess low clearance to minimize
maximal plasma concentrations while achieving a long duration
of maximally eﬀective exposure. Given the ability of parasites
to invade the CNS, it is also necessary that the compound
readily penetrate the blood−brain barrier. Finally, improving
TgDHFR potency can reduce eﬀective dose levels and decrease
the likelihood of compound related oﬀ-target pharmacology
and associated side eﬀects and toxicity.
In this study, we report on the SAR and lead optimization
strategy underlying the discovery of 5-(4-(3-(2-methoxypyrimidin-5-yl)phenyl)piperazin-1-yl)pyrimidine-2,4-diamine 3, a
selective and potent TgDHFR inhibitor with properties
consistent with those outlined above supporting the ﬁrst
standalone treatment for toxoplasmosis.

Figure 1. Dose−response curve of 1 for inhibition of T. gondii DHFR
and human DHFR. The shaded blue area represents the
concentration of 1 with >80% inhibition of TgDHFR and 5−35%
hDHFR.

associated dose limiting mechanism-based toxicity.33 The
concentration of 1 that gives signiﬁcant inhibition of TgDHFR,
i.e., > IC80, begins to also inhibit hDHFR by 5−35%. On the
basis of these data, it seemed reasonable that at least an order
of magnitude and preferably 20-fold increase in selectivity in a
new compound would be suﬃcient to overcome the
mechanism-based toxicity issues observed with 1 and possibly
enable a standalone therapy.
Early Proﬁling Data for Lead 2 and Comparison to
DHFR Inhibitor Reference Standard Drugs. The structures of lead 230 and DHFR inhibitor reference compounds
pyrimethamine (1), trimethoprim (4), methotrexate (5), and
trimetrexate (6) are shown in Figure 2. The DHFR inhibitory
activity and selectivity, kinetic solubility, human liver microsomal intrinsic clearance, and permeability and eﬄux across an
MDR1-MDCK cell monolayer for lead 2 and reference
compounds 1, 4, 5, and 6 are shown in Table 1. Lead 2 has
a TgDHFR IC50 of 8.76 ± 1.0 nM with 79-fold selectivity
relative to the human enzyme. This is 6.6-fold more selective
than 1. Although this improvement in selectivity was
encouraging, in our view is insuﬃcient to achieve a standalone treatment. Trimethoprim 4, sometimes used oﬀ label in
combination with sulfamethoxazole for the treatment of
toxoplasmosis,was about 240-fold less potent against TgDHFR
than 1 with an IC50 of 33 100 nM and selectivity index of 15.
Methotrexate 5 was far more potent than 1, 4, or 2 for
inhibiting hDHFR with an IC50 of 4.74 nM. Interestingly, 5 has
the opposite selectivity proﬁle as compared to 1, where it is 17fold less potent for inhibiting TgDHFR (IC50 of 78.3 nM),
giving a selectivity ratio of 0.061. Trimetrexate 6, which
structurally is a combination of the diaminopteridine head of 5
and trimethoxybenzyl tail of 4, is nearly equally active at
TgDHFR and hDHFR with respective IC50’s of 1.35 and 4.07
nM, giving a selectivity index of 3.0.
Further characterization of 1 and 2 was performed to
benchmark and guide a lead optimization strategy (Table 1).
Lead 2 has low kinetic and thermodynamic solubility (<4 μM),
high clearance in human liver microsomes (HLM) (i.e., > liver
blood ﬂow), and low to moderate MDCK-MDR1 permeability,
all areas for improvement during lead optimization. Interestingly, 1, which was discovered and developed in the 1940s, has
near ideal CNS drug properties in terms of solubility, HLM
stability, and MDR1-MDCK permeability. Properties for 1 and
2 are summarized in Table 2, with the main diﬀerences being
an increase in both MW and log P for 2, which likely
contributes to its undesirable solubility, metabolic stability, and
permeability proﬁle. On the basis of these data, lead

■

RESULTS AND DISCUSSION
Pyrimethamine Selectivity and Potency. Pyrimethamine 1 is reported to be 7.6-fold more selective for TgDHFR
compared to hDHFR with a hDHFR IC50 of 760 ± 130 nM for
inhibiting conversion of dihydrofolate to tetrahydrofolate.31
More recently, the Ki for hDHFR was reported to be 470
nM.32 In our hands, 1 has an IC50 for inhibiting TgDHFR of
139 ± 49 nM (Figure 1), which makes it 12-fold more potent
for inhibiting TgDHFR over hDHFR. Although this level of
selectivity is suﬃcient to make 1 a preferred DHFR inhibitor
for the treatment of toxoplasmosis, as can be seen in Figure 1,
it is not suﬃcient to preclude inhibition of hDHFR and
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Figure 2. Reference compounds pyrimethamine (1), trimethoprim (4), methotrexate (5), trimetrexate (6) and initial lead TRC-19 (2).

Table 1. Evaluation of Comparator Compounds on DHFR Inhibition, Kinetic Solubility, Clearance in Human Liver
Microsomes, and MDR1-MDCK Permeability
compd

TgDHFRa IC50 (nM)

hDHFRaIC50 (nM)

selectivity indexb

solubilityc (μM)

HLM (mL min−1 kg−1)

MDR1-MDCKd

1
2
4
5
6

139 ± 14
8.76 ± 1.0
33,100 ± 3400
78.3 ± 6.7
1.35 ± 0.07

1680 ± 230
689 ± 39
503,000 ± 51,000
4.74 ± 0.36
4.07 ± 0.11

12
79
15
0.061
3.0

184
3.9

<8.6
28.4
<8.6

36 (0.83)
2.7 (0.62)
7.5 (3.5)

a
Average of at least three independent replicates ± SEM. bSelectivity index (SI) is the hDHFR IC50/TgDHFR IC50, determined within the same
experiment. cKinetic solubility. dA:B (Papp 10−6 cm/s) (ER), where ER is eﬄux ratio deﬁned as permeability in B:A/A:B directions.

Table 2. Properties of 1 and 2a
compd

MW

cLogP

1
2

248.7
346.4

3.00
3.74

log P
2.71
3.38

b

TPSA

cSol (μM)

76.8
83.2

135
3.09

IC50 of 31 nM. Meta-methyl and meta-chloro analogs 11 and
14 respectively were more potent and selective than
corresponding para-substituted compounds 12 and 15,
supporting the hypothesis based on modeling that metasubstituents would be preferred. Encouragingly, meta-methyl
11, while 8-fold less potent than 2, maintained equivalent
selectivity of 79-fold. On the basis of these ﬁndings, design
focused on meta-substituents to further probe this apparently
important pocket for both selectivity and potency. Metamethoxy 16, meta-triﬂuoromethyl 17, meta-triﬂuoromethoxy
18, and meta-cyclopropyl 19 all had reduced potency and
selectivity as compared to meta-phenyl lead 2. Adding a methyl
or ethyl to the 6-position of the diaminopyrimidine group,
giving 20 and 21 respectively, maintained or slightly improved
potency over 2 but with a slight loss in selectivity.
Structure−Activity Relationships for Heteroaryl Analogs of Meta-Biphenyl 2. We then turned our focus toward
improving the solubility and metabolic stability issues observed
with early lead 2 by preparing a variety of heteroaryl analogs
(Table 4). We hypothesized that the distal phenyl ring of 2 was
the likely site of metabolism and that introducing nitrogen
molecules into this ring would block metabolism and increase
solubility. The 2-, 3- and 4-pyridine analogs 22, 23, and 24
maintained or slightly improved potency and selectivity but
without much improvement in solubility. The potency of 3pyridine analog 23 is noteworthy at 2.7 nM, about 3.3-fold
more potent than 2, and with a selectivity index of 112-fold.
Addition of a second nitrogen into this ring to give
pyrimidines, pyridazines, and pyrazines provided analogs with
variable improvements in potency, selectivity, solubility, and
HLM metabolic stability. 5-Pyrimidine analog 26 stood out

a

Calculated properties were performed using ChemDraw Professional
software version 17.0.0.206 (121). bMeasured log P was performed at
pH 11.0 in octanol/buﬀer.

optimization was initially focused on understanding the SAR
underlying selectivity and potency while simultaneously
designing analogs with lower cLogP and higher calculated
solubility in an eﬀort to improve physical chemical properties.
Structure−Activity Relationships for Analogs of 2.
Structure−activity relationship (SAR) data based on 2 for
inhibition of TgDHFR and selectivity relative to hDHFR are
shown in Tables 3−5. Initial optimization of 2 focused on a
systematic approach to gain a better understanding of its SAR
with emphasis on improving DHFR selectivity (Table 3). As a
basis for comparison, unsubstituted analog 7 was prepared and
found to lose potency (IC50 = 209 nM) but maintained a
similar selectivity index (59-fold) relative to initial lead 2.
Ortho-phenyl 8 and para-phenyl 9 were both about 4-fold less
potent (IC50 ∼ 30 nM) than 2 but diﬀered in their selectivity
proﬁles. Ortho-phenyl 8 maintained similar selectivity as 2 at
58-fold, whereas para-phenyl 9 had reduced selectivity at 11fold. These data are consistent with modeling predictions of
the binding cavity.30 Replacing the distal meta-phenyl of 2 with
an ortho-methyl 10 or ortho-chloro 13 resulted in complete
loss of activity at the highest doses tested. This result is
surprising considering ortho-phenyl analog 8 had a TgDHFR
1564
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Table 3. Structure−Activity Relationships of Phenylpiperazine Analogs on Inhibition of TgDHFR and hDHFR

compd

R2

R1

TgDHFRa IC50 (nM)

hDHFRa IC50 (nM)

selectivity indexb

2
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

3-phenyl
H
2-phenyl
4-phenyl
2-Me
3-Me
4-Me
2-Cl
3-Cl
4-Cl
3-MeO
3-CF3
3-CF3O
3-cyclopropyl
3-phenyl
3-phenyl

H
H
H
H
H
H
H
H
H
H
H
H
H
H
Me
Et

8.76 ± 1.0
209 ± 28
30.9 ± 2.2
31.5 ± 2.7
>10000
75.3 ± 5.5
181 ± 14
>10000
39.8 ± 5.3
45.9 ± 7.3
57.8 ± 3.4
62.1 ± 5.2
12.9 ± 1.1
29.0 ± 1.7
9.19 ± 0.94
3.91 ± 0.61

689 ± 39
12,500 ± 1200
1790 ± 190
347 ± 23
>30000
5980 ± 320
3260 ± 110
>30,000
1540 ± 170
1090 ± 140
2710 ± 150
541 ± 43
819 ± 36
1630 ± 45
237 ± 21
200 ± 16

79
59
58
11
not available
79
18
not available
39
24
47
8.7
63
56
26
51

Average of at least three independent replicates ± SEM. bSelectivity index (SI) is the hDHFR IC50/TgDHFR IC50.

a

Table 4. Evaluation of Heteroaryl Replacements of the Distal Phenyl of 2 on DHFR Inhibition, Selectivity, Solubility, Human
Liver Microsomal Clearance, and MDCK-MDR1 Permeability

compd

R2

22
23
24
25
26
27
28

2-pyridine
3-pyridine
4-pyridine
2-pyrimidine
5-pyrimidine
2-pyrazine
4-pyridazine

TgDHFRa IC50 (nM)

hDHFRa IC50 (nM)

selectivityb

±
±
±
±
±
±
±

1360 ± 210
300 ± 55
468 ± 32
1300 ± 51
1430 ± 100
1330 ± 50
1100 ± 130

132
112
108
47.6
301
129
185

10.3
2.68
4.34
27.3
4.75
10.3
6.00

1.6
0.12
0.43
2.3
0.34
0.39
0.70

solubilityc (μM)

HLMd (CLint)

12

17.7

2.2
180
>200
1.6
5.7

18.7
<8.6
<8.6
<8.6
<8.6

MDR1-MDCKe

17.4
31.7
20.2
19.3
6.40

(0.86)
(0.80)
(1.2)
(0.77)
(3.8)

Average of at least three independent replicates ± SEM. bSelectivity index (SI) is the hDHFR IC50/TgDHFR IC50, determined within the same
experiment. cKinetic solubility. dHLM, human liver microsome; CLint, intrinsic clearance (mL min−1 kg−1). eA:B permeability (Papp 10−6 cm/s),
where ER is eﬄux ratio deﬁned as permeability in B:A/A:B directions.
a

with a 307-fold TgDHFR selectivity index and a TgDHFR IC50
of 5.2 nM, as well as markedly improved solubility (>200 uM)
and metabolic stability (Clint < 8.6 mL min−1 kg−1). The
improvement in selectivity observed for 26 is nearly 4 times
that of early lead 2 and 25-fold better than 1. 2-Pyrazine 27
and 4-pyridazine 28 had promising potency with IC50 values of
10 and 6.0 nM, respectively, and selectivity indexes of 129 and
185-fold, respectively, but both were hampered with low
kinetic solubility, precluding additional investigation with these
chemotypes. In general, heteroaryl substitutions increase
TgDHFR selectivity and maintain or slightly improve potency
relative to 2. The 2-fold improvement in selectivity observed
for 5-pyrimidine analog 26 compared to the 3-pyridyl analog
23 may result from one of the nitrogen atoms on the distal
pyrimidine ring being forced to make an unfavorable

interaction in hDHFR. The 3-pyridyl analog 23, which can
rotate the nitrogen away from such an unfavorable interaction,
is about 5-fold more potent at hDHFR than pyrimidine 26 (
hDHFR IC50 = 1430 nM).
SAR for the Distal 5-Pyrimidine Ring of 26. Next, we
evaluated if selectivity could be further improved by adding
substitutions onto the 2-position of the distal 5-pyrimidine ring
of 26 (Table 5). On the basis of the crystal structure and
modeling (see Figures 3 and 4), it appeared that substitutions
at this position were not likely to have steric eﬀects as they
pointed into solvent space. However, if the pyrimidine
nitrogen atoms were making a favorable hydrogen bond
interaction with TgDHFR His-27 and an unfavorable
interaction with hDHFR Pro-26, then electron donating
substituents would be predicted to enhance potency and
1565
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Table 5. Evaluation of Substitutions on the Distal Pyrimidine Ring of 26 on DHFR Inhibition, Selectivity, Solubility, Human
Liver Microsomal Clearance, and MDCK-MDR-1 Permeability

compd

R3

29
3
30
31

Me
MeO
CF3
cyclopropyl

TgDHFRa IC50 (nM)

hDHFRaIC50 (nM)

selectivity indexb

solubility (μM)c

HLMd(CLint)

MDR1-MDCKe

±
±
±
±

935 ± 46
308 ± 71
2800 ± 470
973 ± 120

237
196
85.6
98

150
186
17
12

<8.6
<8.6
10.5
17.4

19.3 (1.2)
20.1 (1.1)

3.95
1.57
32.7
9.92

0.26
0.42
3.3
0.83

Average of at least three independent replicates ± SEM. bSelectivity index (SI) is the hDHFR IC50/TgDHFR IC50, determined within the same
experiment. cKinetic solubility. dHLM, human liver microsome; CLint, intrinsic clearance (mL min−1 kg−1). eA:B permeability (Papp 10−6 cm/s),
where ER is eﬄux ratio deﬁned as permeability in B:A/A:B directions.
a

IC50 of 1.57 nM but a slightly reduced selectivity index of 196.
Triﬂuoromethyl 30 and cyclopropyl 31 were signiﬁcantly less
potent against TgDHFR, less selective and had low kinetic
solubility. The loss in selectivity with these analogs is
principally driven more by loss of activity against TgDHFR
rather than by gaining potency at hDHFR.
Further characterization of 3 demonstrated good kinetic
solubility of 186 μM at pH 7.4, low human microsomal
clearance (<8.6 mL min−1 kg−1), and high permeability in
MDR1-MDCK cells (20.1 × 10−6 cm/s) with a low eﬄux ratio
of 1.1 (Table 5). In the CEREP 44 safety screen at a 10 μM
dose level, 3 demonstrated good selectivity against all 44
targets tested except for hERG where [3H]dofetilide binding
was inhibited by 60%.
Chemistry. The compounds presented here were synthesized as shown in Schemes 1 and 2. In Scheme 1, substituted
piperazines (36a−n) were condensed with 5-bromouracil 33
in the presence of KF and heating in DMSO to give the
corresponding uracil derivatives 37a−n. Chlorination using
POCl3 and DIPEA provided intermediates 38a−n, followed by
amination reaction using NH3/EtOH at 145 °C to give ﬁnal
products 2, 7−18, 20, 21, and 32. 6-Methyl and 6-ethyl
diaminopyrimidine targets 20 and 21 were synthesized as
described above but starting with the corresponding 6-alkyl-5bromouracils 34 and 35 and condensing with biphenylpiperazine 36a. Piperazine intermediates 36a−n are generally
commercially available or can be prepared by various literature
methods.34,35
Analogs in Scheme 2 were prepared by either Suzuki
coupling of 3-bromophenyl 32 with the corresponding boronic
acids 39o−w to give targets 3, 19, 23, 24, 26, and 28−31 or
Stille coupling of 3-bromophenyl 32 with Sn(Bu)3R2 40x−z to
generate compounds 22, 25, and 27.
Crystal Structure of TgDHFR. To aide in the understanding of the observed selectivity and guide future lead
optimization eﬀorts, several X-ray crystal structures with lead
compounds bound to TgDHFR were solved, including the
complex of 5-pyrimidines 3 and 29 with TgDHFR (Figures 3
and 4). Although at a high-level these data are consistent with
modeling predictions, the crystal structure provides more
subtle clues into why the distal pyrimidine moiety enhances
selectivity. The phenyl groups of 3 and 29 occupy the

Figure 3. Crystal structure of TgDHFR with pyrimidine 29 bound.
Crystal structure data were visualized and modeled using MOE
software from Chemical Consulting Group.

Figure 4. Crystal structure of TgDHFR with pyrimidine 3 bound.
Crystal structure data were visualized and modeled using MOE
software from Chemical Consulting Group.

selectivity. Methyl analog 29 maintained TgDHFR potency
(IC50 = 3.95 nM) with only a slight reduction in selectivity
(237-fold) relative to unsubstituted 5-pyrimidine 26. Methyl
analog 29 had good solubility, HLM stability, and MDCKMDR1 permeability. An electron donating 2-methoxy
substituent gave 3, with excellent TgDHFR potency with an
1566
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Scheme 1. Synthesis of Compounds 2, 7−18, 20, 21, and 32a

a 2
R = (a) 3-phenyl, (b) hydrogen, (c) 2-phenyl, (d) 4-phenyl, (e) 2-methyl, (f) 3-methyl, (g) 4-methyl, (h) 2-chloro, (i) 3-chloro, (j) 4-chloro, (k)
3-methoxy, (l) 3-triﬂuoromethyl, (m) 3-triﬂuoromethoxy, (n) 3-bromo. Reagents and conditions: (a) KF, DMSO, 110 °C, 12 h; (b) POCl3,
DIPEA, 110 °C, 5 h; (c) NH3, EtOH, 145 °C, 24 h.

Scheme 2. Synthesis of Compounds 3, 19, 22−31a

morphisms related to these amino acids that would alter
selectivity.37
Parasiticidal and Antiproliferative Eﬀects of 5Methoxypyrimidine 3 in Cell-Based Models. Optimized
pyrimidine 3 and comparator drug 1 were evaluated in cellbased models to investigate translation of the respective DHFR
inhibitory activities into parasiticidal and antiproliferative host
cell eﬀects. Lead 3 had a parasiticidal EC50 of 13 nM and 1 had
an EC50 of 680 nM against the type I RH strain of T. gondii.
The 52-fold improvement in potency of 3 over 1 in this assay is
consistent with its 89-fold potency advantage for inhibiting
TgDHFR. Antiproliferative eﬀects of these compounds in
human MCF-7 cells, measured using the MTT assay, were
consistent with the human DHFR data, wherein 1 and 3 had
EC50 values of 11 600 nM and 7300 nM, respectively. The
selectivity of both 1 (17-fold) and 3 (560-fold) in the cellbased assays (Table 6) is in line with their DHFR selectivity

a 2

R = (o) 5-(2-methoxypyrimidine), (p) cyclopropyl, (q) 3-pyridine,
(r) 4-pyridine, (s) 5-pyrimidine, (t) 4-pyridazine, (u) 5-(2methylpyrimidine), (v) 5-(2-triﬂuoromethylpyrimidine), (w) 5-(2cyclopropylpyrimidine), (x) 2-pyridine, (y) 2-pyrimidine and (z) 2pyrazine. Reagents and conditions: (a) Pd(PPh3)4, R2-B(OH)2 (39o−
w), Cs2CO3, dioxane/H2O, 110 °C; or (b) Pd2(dba)3, Sn(nBu)3-R2
(40x−z), XPhos, dioxane, 100 °C.

TgDHFR cavity created near F91 and G22 (Figure 4), while
the residues present in hDHFR at these positions appear to be
less accommodating. These TgDHFR phenylalanine residues
(F32 and F91) create a more enclosed hydrophobic area
around the phenyl ring connected to the piperazine. This
conﬁguration also positions the distal heteroaromatic ring into
the glycine site, possibly enabling a hydrogen bonding
interaction with His27 in the T. gondii enzyme (Figure 3).
The presence of a proline residue (Pro26) in hDHFR, at the
analogous position of His 27 in TgDHFR, provides a
hypothesis for the observed subtle improvement in selectivity
with the 5-pyrimidines. The TgDHFR His27 may enable a
favorable H-bond with a pyrimidine N, whereas this would not
be feasible in the human enzyme. In addition, there could be
an unfavorable interaction in the hDHFR between the
pyrimidine nitrogen atoms of 3 and Pro 26. This interaction
might help explain why 3-pyridine 23 is less selective than
pyrimidine 3, as the pyridine N could rotate away from the
proposed unfavorable interaction with Pro26 in the human
enzyme. We hypothesize these are the likely reasons for the
observed TgDHFR selectivity. However, it is also noted that
N64 in hDHFR blocks π−π interactions. Interactions at these
residues are well supported by the literature and may also
contribute to the observed TgDHFR selectivity.36 A search of
UniProt shows that there are no reported human poly-

Table 6. Parasiticidal Activity for 1 and 3 in T. gondii
Infected Human Foreskin Fibroblast Cells As Compared to
the Antiproliferative Eﬀects of 1 and 3 in MCF-7 Cells
compd

T. gondii cell-based
EC50 (nM)a

MCF-7
EC50 (nM)b

selectivity
indexc

3
1

13 ± 3.8
680 ± 210

7300
11700

560
17

a
EC50 = half maximal response concentration, average of at least three
experiments (±SD). bMCF-7 cell viability determined using the MTT
assay in triplicate (n = 1). cSelectivity index calculated as the MCF-7
EC50/Tg cell-based EC50.

proﬁles of 12- and 200-fold, respectively. These data are
important as they demonstrate that 3 has antiparasiticidal
activity with similar eﬃcacy as 1, but with substantially better
potency and selectivity (Figure 5).
Comparison of Potency against Additional Strains of
Toxoplasma. Given the enhanced potency of 3, we wanted to
test it against diﬀerent lineages of T. gondii. Consequently, we
chose a series of low passage isolates that are representative of
the major genotypes of T. gondii seen in human infection from
diﬀerent regions of the world. As we have previously described,
the population structure of T. gondii comprises six major
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resistance to pyrimethamine as described previously,50 but
interestingly this did not lead to cross-resistance to 3.
Mouse Pharmacokinetic and Brain to Plasma Exposure Studies. 2-Methoxypyrimidine 3 was selected over 2methylpyrimidine 29 and unsubstituted pyrimidine 26 for
further in vivo characterization owing to its substantially
improved stability in mouse liver microsomes (MLMs).
Preclinical models of toxoplasmosis are primarily performed
in mice, and therefore a compound with suﬃcient oral
bioavailability and plasma and CNS exposure to support
murine eﬃcacy testing was desired. Fortunately, 3 had
moderate mouse liver microsome (MLM) intrinsic clearance
(Clint) of 56.3 mL min−1 kg−1, which is 63% of mouse liver
blood ﬂow (LBF), whereas 29 and 26 both had high predicted
clearance with MLM Clint values of 431 and 2700 mL min−1
kg−1, respectively, multiples above mouse LBF. The oral and iv
PK parameters in mouse are summarized in Table 8.
Compound 3 has low to moderate clearance of 10.6 mL
min−1 kg−1, a volume of distribution of 1.14 L/kg, and a halflife of 3.9 h after a 1.0 mg/kg, iv dose. Oral bioavailability after
a 0.83 mg/kg po dose was 47.3% with a Cmax of 178 ng/mL 30
min after dosing. The unbound fraction (%) in mouse plasma
is 8.7 ± 0.2 and in brain homogenate 2.4 ± 0.3, determined
using an equilibrium dialysis method. Compound 3 was freely
permeable into the mouse CNS at 0.5 h after a 10 mg/kg oral
dose; the concentration in brain was 2560 ± 240 ng/g and in
blood 1610 ± 580 ng/mL, giving a brain to blood ratio of 1.7
± 0.6.
In Vivo Eﬃcacy of 1 and 3 in a Murine Model of
Acute Toxoplasmosis. Compounds 1 and 3 were tested
independently in a murine model of acute toxoplasmosis and
observed to improve survival in a dose-dependent manner
(Figure 6a and Figure 6b). Female CD-1 mice were inoculated
intraperitoneally (ip) with 3000 tachyzoites of the highly
virulent RH strain of T. gondii on day 0. In parallel, three
negative control mice were inoculated with vehicle, lacking the
parasite. The parasite strain used in this study was genetically
modiﬁed to constitutively express the enzyme luciferase and
enable infection monitoring via an in vivo imaging system
(IVIS).51 Mice were monitored for survival for 30 days with
intermittent IVIS monitoring (data not shown). On day 4 of
dosing, compound exposure was assessed by microsampling
from tail vein from three mice per group at 1, 4, and 12 h
postdose and three mice per group at 2, 8, and 24 h postdose
(data shown in Figure 7a and Figure 7b).
Compound 3 at doses of 10 mg/kg, q.d. or b.i.d. for 7 days,
yielded 100% survival for 30 days (end of study), while doses
of 1 and 3 mg/kg produced similar results on survival as
comparator compound 1 did at 18 mg/kg b.i.d. and 54 mg/kg
q.d., respectively. Survival data for 1 in this study were
consistent with published literature.52−54 All mice treated with
vehicle died within 6−7 days. It should be noted that the single
animals that were lost in the 3 mg/kg compound 3 group and
54 mg/kg compound 1 group were believed to be due to
handling errors during imaging rather than active T. gondii
infection as no signs of infection or bioluminescence (data not
shown) were observed for these animals during the study.
Consistent with the improved in vitro potency of 3 relative to
1, it was also more potent in vivo producing similar eﬃcacy at
doses about 18-fold lower.
Cure rates were assessed by subinfection of naive mice with
combined homogenized brain and lung tissue from mice that
survived 30 days. The tissues from two surviving mice of the

Figure 5. Parasiticidal dose−response curves of 1 and 3 in T. gondii
infected human foreskin ﬁbroblast cells.

clades, each of which contains several related lineages.38 The
majority of human cases of toxoplasmosis in Europe and North
America are due to type 2 strains,39−41 and we typically use a
laboratory strain called ME49 as representative for such strains.
The ME49 strain was originally isolated from a sheep in the
United States,42 and it reﬂects the genotype of many strains
found in food animals and which cause human toxoplasmosis.
The CTG strain was originally isolated from a cat in the
United States, and it represents a common genotype found in
animals, although it is relatively rare in humans.43 Type 1
strains are also reasonably abundant in North America, and
they are of interest as they are more pathogenic in many hosts
including immunocompromised humans.41,44 Although most
lab studies use the type 1 RH strain, use of the GT1 strain is
preferable as it preserves the entire lifecycle.45 The GT1 strain
was originally isolated from a goat in North America,46
although it is genetically similar to a number of human isolates
including the RH strain. In contrast to North America and
Europe, strains in South America are dominated by highly
pathogenic lines such as types 5 (reference strain RUB) and 10
(reference strain VAND).38 The VAND and RUB strains were
isolated from severe human cases of toxoplasmosis that are
characteristic of the Amazon region.47,48 These strains have
also been used as reference strains for the Toxoplasma
comparative genomes paper.49
To monitor the eﬀects of new antiparasitic compounds on
diﬀerent strains of T. gondii, we generated ﬁre ﬂy luciferase
(FLUC) expressing lines so that we could use a common
luciferase-based growth assay to monitor growth inhibition.
We compared the potency of 3 for its ability to inhibit the
growth of T. gondii strains in vitro. As shown in Table 7, the
Table 7. Growth Eﬀects of 3 on Diﬀerent Strains of T.
gondiia
strain

host of origin

geographic distribution

type

EC50 (nM)

GT1
ME49
CTG
RUB
VAND

goat
sheep
cat
human
human

North America
North America, Europe
North America
South America
South America

1
2
3
5
10

18.0 ± 9.3
8.3 ± 2.9
29.8 ± 15.4
7.6 ± 3.3
11.2 ± 0.5

Average of at least three independent replicates ± SEM.

a

potency of 3 was highly similar across these diﬀerent lineages,
with only 2- to 4-fold diﬀerences being observed in potency.
The FLUC lines used here also carry a pyrimethamine
resistance allele of DHFR that was used to generate the
transgenic lines. This resistant DHFR allele confers highly level
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Table 8. Pharmacokinetics of Compound 3 in Mousea
route

dose (mg/kg)

iv
po

1.0
0.83

F (%)
47.3

Cmax,po (ng/mL)
178

Tmax,po (h)

AUC0−last,po (ng·h/mL)

0.05

CLiv (mL min−1 kg−1)

Vdiv (L/kg)

t1/2,iv (h)

10.6

1.14

3.9

750

a
Oral bioavailability (F), area under the concentration−time curve from time zero to the last measurable concentration (AUC0−last), clearance
(CL), maximum observed plasma concentration (Cmax), intravenous (iv), per os (po), elimination half-life (t1/2), time to Cmax (Tmax), volume of
distribution (Vd).

Figure 6. (a) Kaplan−Meier survival curves of compound 1 in CD-1 female mice (n = 12 for drug treated groups, n = 9 for vehicle group) infected
with 3000 RH type 1 T. gondii tachyzoites on day 0 followed by oral administration of 1 beginning on day 1 through day 7. Mice were carefully
monitored for signs of infection, including by intermittent imaging (data not shown). (b) Kaplan−Meier survival curves of compound 3 in CD-1
female mice (n = 12 for drug treated groups, n = 9 for vehicle group) infected with 3000 RH type 1 T. gondii tachyzoites on day 0 followed by oral
administration of 3 beginning on day 1 through day 7. Mice were carefully monitored for signs of infection, including by intermittent imaging (data
not shown).

is clear both 1 and 3 are strongly eﬃcacious in eradicating the
tissue damaging and life threatening tachyzoite form of the
parasite.
Compound 3 had a cure rate of 50% in the 1 and 3 mg/kg
groups and 100% in the 10 mg/kg groups. Pyrimethamine 1
was 100% curative at the 54 mg/kg dose and 33−67% curative
at the 18 mg/kg b.i.d. dose. These data suggest that inhibition
of TgDHFR is suﬃcient for maximal eﬃcacy as a stand-alone
therapy (e.g., without coadministration of a DHPS inhibitor).

same dosing group were injected into one donor mouse.
Infection with a single T. gondii parasite of the type I RH strain
is believed to be 100% lethal in naive mice;45 therefore,
subinoculated naive mice that survived for 15 days and were
without signs of infection was indicative of a cure (i.e., the
donor mice were devoid of parasite). It should be noted that
the RH strain of T. gondii does not typically form tissue cysts.
Therefore, a cure in this model may not translate to a cure with
clinically relevant strains that form tissue cysts. Nonetheless, it
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EXPERIMENTAL SECTION

Materials and Methods. General. All synthetic chemistry,
DMPK, T. gondii DHFR crystal structures with 3 and 29, and DHFR
in vitro pharmacology were performed at WuXi App Tec at the China
facilities in Tianjin and Shanghai. Work with Toxoplasma gondii was
performed at Evotec in Manchester, U.K., and in Prof. Sibley’s lab at
Washington University, St. Louis, MO. Proton NMR spectra were
recorded on a Varian 400 MHz NMR. LC/MS data were taken on a
quadrupole mass spectrometer on Shimadzu LC/MS 2010 (column
Sepax ODS 50 mm × 2.0 mm, 5 μm) or Agilent 1200 HPLC, 1956
MSD (column Shim-pack XR-ODS 30 mm × 3.0 mm, 2.2 μm)
operating in ES (+) ionization mode. All ﬁnal compounds were
greater than 95% pure based on HPLC UV% AUC. Structures were
determined by 1H NMR and LC/MS. Final compounds in this
manuscript are not known to interfere with the assays herein (i.e.,
they are not PAINS).
All animal studies were conducted at WuXi App Tec in China and
Evotec in Manchester, U.K., and were performed in accordance with
the institutional guidelines for these countries and laboratories.
LC/MS methods. Method A. Method A was run on a Shimadzu
LC-20AB with a MS 2010 detector using a Luna-C18(1) column (2.0
mm × 30 mm, 3 μm) at 40 °C. Mobile phase A was 0.037% (v/v)
aqueous TFA, and mobile phase B was 0.018% (v/v) TFA in
acetonitrile. The ﬂow rate was 0.8 mL/min from 0.01 to 1.51 min,
then 1.2 mL/min from 1.52 to 2.00 min. The gradient ran from 90%
mobile phase A to 10% mobile phase A over 1.15 min, then remained
at 10% mobile phase A through 1.65 min, then back to 90% mobile
phase A at 1.66 min and was maintained at 90% mobile phase A
through 2.0 min. The UV detection was 220 nm, and the MS was
measured in positive ion mode.
Method B. Method B was run on an Agilent 1200 with a MS 6120
detector using an Xbridge Shield RP18 column (2.1 mm × 50 mm, 5
μm) at 40 °C. Mobile phase A was 10 mM aqueous NH4HCO3, and
mobile phase B was acetonitrile. The ﬂow rate was 1.0 mL/min from
0.01 to 2.48 min, then 1.2 mL/min from 2.50 to 3.00 min. The
gradient ran from 90% mobile phase A to 20% mobile phase A over
2.00 min, then remained at 20% mobile phase A through 2.48 min,
then back to 90% mobile phase A at 2.50 min and maintained at 90%
mobile phase A through 3.0 min. The UV detection was 220 nm, and
the MS was measured in positive ion mode.
Method C. Method C was run on an Agilent 1200 with a MS 6120
detector using an Xbridge Shield RP18 column (2.1 mm × 50 mm,
5um) at 40 °C. Mobile phase A was 10 mM aqueous NH4HCO3, and
mobile phase B was acetonitrile. The ﬂow rate was 1.0 mL/min from
0.01 to 2.50 min, then 1.2 mL/min from 2.51 to 3.00 min. The
gradient ran from 70% mobile phase A to 10% mobile phase A over
1.50 min, then remained at 10% mobile phase A through 2.50 min,
then back to 70% mobile phase A at 2.51 min and maintained at 70%
mobile phase A through 3.0 min. The UV detection was 220 nm, and
the MS was measured in positive ion mode.
Method D. Method D was run on an Agilent 1200 with a MS
6120 detector using a Venusil XBP-C18 column (2.1 mm × 50 mm, 5
μm) at 40 °C. Mobile phase A was 0.0375% aqueous TFA and mobile
phase B was 0.018% TFA in acetonitrile. The ﬂow rate was 0.8 mL/
min from 0.01 to 4.5 min. The gradient was maintained at 99%
mobile phase A from 0.00 to 0.40 min, then the gradient ran from
99% mobile phase A to 10% mobile phase A over 3.00 min, then to
0% mobile phase A over 0.45 min, then back to 99% mobile phase A
over 0.01 min and maintained here for 0.55 min. The UV detection
was 220 nm, and the MS was measured in positive ion mode.
Chemistry. The compounds in Figure 2 were sourced as follows.
Compound 2 was prepared as described previously.30 Pyrimethamine
(1) was sourced from the drug manufacturer, and 1H NMR and LC/
MS data conﬁrmed structure and purity of 99.9%. Trimethoprim (4)
was purchased from a commercial supplier as the lactate salt, and 1H
NMR and LC/MS data conﬁrmed structure with a purity of 98.7%.
Methotrexate (5) was purchased from a commercial supplier, and 1H
NMR and LC/MS data conﬁrmed structure with a purity near 100%.
Trimetrexate (6) was purchased from a commercial supplier as the

Figure 7. (a) Day 4 [plasma]free exposure of 1 from the acute murine
model of toxoplasmosis plotted as free plasma (nM) levels versus
time. (b) Day 4 [plasma]free exposure of 3 from the acute murine
model of toxoplasmosis plotted as free plasma (nM) levels versus
time.

Regarding the results for pyrimethamine 1, the human
equivalent dose of 54 mg/kg in mouse (approximately 300
mg/day in a 70 kg individual) cannot be administered in
patients owing to dose-limiting, mechanism-based safety issues.
For both compounds, the onset of eﬀect on survival time
occurred at exposures near or slightly above the T. gondii cellbased EC50 values (1.0 mg/kg for 3 and 18 mg/kg for 1), with
maximal eﬀects occurring at dose levels of 3 mg/kg and 10
mg/kg for 3 and 54 mg/kg for 1 (Figure 7a and Figure 7b),
which exceed the cell-based EC50 values.

■

CONCLUSIONS
Rational drug design led to the identiﬁcation of several highly
selective and potent arylpiperazine-based TgDHFR inhibitors.
The structure−activity relationship for these compounds
provides proof-of-concept for the feasibility of discovering a
next generation toxoplasmosis treatment with improved
potency, selectivity, and safety. 2-Methoxypyrimidine 3, with
16-fold better selectivity for TgDHFR and 89-fold better
potency as compared to pyrimethamine 1 and with desirable
DMPK and safety properties, was selected for exploration in
preclinical models of toxoplasmosis. Compound 3 was eﬀective
in radical cure of acute infection with the highly virulent type I
RH strain in the murine model and showed similar potency
across multiple parasite lineages in cell-based parasite growth
assays. On the basis of the eﬃcacy observed, we hypothesize it
will be feasible to achieve parasiticidal levels of 3 in patients
that are below concentrations that would inhibit hDHFR, thus
providing a safer and more eﬃcacious therapy than is currently
available and possibly obviating the need for sulfonamide
combination therapy.
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trihydrochloride salt, and 1H NMR and LC/MS data conﬁrmed
structure with a purity of 95.2%.
The compounds in Tables 3, 4, and 5 were prepared according to
Schemes 1 and 2.
Compounds 7−18, 20, and 21 were prepared in a similar fashion as
described below for the synthesis of 32.
5-(4-(3-Bromophenyl)piperazin-1-yl)pyrimidine-2,4-diamine (32). 32 was prepared in 3 steps and 12.8% overall yield as
follows.
Step 1. 5-(4-([3-Bromophenyl])piperazin-1-yl)pyrimidine-2,4(1H,3H)-dione (37n). To a mixture of 5-bromo-1H-pyrimidine-2,4dione 33 (7.92 g, 42 mmol, 1.0 equiv) and 1-(3-bromophenyl)piperazine 36n (10.0 g, 42 mmol, 1.0 equiv) in DMSO (200 mL) was
added potassium ﬂuoride (5.0 g, 94 mmol, 2.0 equiv). The resulting
mixture was stirred at 130 °C for 12 h, cooled to room temperature,
and poured into 300 mL of water. The precipitate was collected by
suction ﬁltration, washed with 200 mL of EtOH, and dried in vacuo
leaving 5-(4-([3-bromophenyl])piperazin-1-yl)pyrimidine-2,4(1H,3H)-dione 37n as a brown solid (10.6 g, 30.2 mmol, 73.5%
yield) used as such in the next step. LC/MS method B (ESI+):
expected m/z 351 (M + 1)+; found m/z 351 (M + 1)+, tR = 1.07 min.
Step 2. 5-(4-(3-Bromophenyl)piperazin-1-yl)-2,4-dichloropyrimidine (38n). A mixture of 5-(4-(3-bromophenyl)piperazin-1-yl)pyrimidine-2,4(1H,3H)-dione 37n (10 g, 28.5 mmol, 1.0 equiv)
and DIPEA (14.4 g, 111 mmol, 3.9 equiv) in 70 mL of toluene was
cooled to 10 °C, and POCl3 (15.8 g, 103 mmol) was added over 1 h,
keeping the reaction temperature 20 °C. The mixture was stirred at 20
°C for 1 h, heated to 95 °C, and held at 95 °C for 12 h. LC/MS was
consistent with the desired product MS. The reaction mixture was
concentrated under reduced pressure to give a black residue, which
was diluted with cold water (200 mL) and extracted with DCM (3 ×
100 mL). The combined organic layers were washed with brine (2 ×
100 mL), dried over Na2SO4, ﬁltered, and concentrated under
reduced pressure to give 5-(4-(3-bromophenyl)piperazin-1-yl)-2,4dichloropyrimidine (38n) (6.4 g, 58% yield, 90.8% HPLC purity) as a
yellow solid used as such in the next step. LC/MS method C (ESI+):
expected m/z 389.1 (M + 1)+; found m/z 389.0 (M + 1)+, tR = 2.18
min.
Step 3. 5-(4-(3-Bromophenyl)piperazin-1-yl)pyrimidine-2,4-diamine (32). A mixture of 5-(4-(bromophenyl)piperazin-1-yl)-2,4dichloropyrimidine 38n (100.0 mg, 0.26 mmol, 1.0 equiv) in NH3/
EtOH (10 mL) was added to a steel bomb. The mixture was stirred at
145 °C for 12 h. The suspension was cooled to room temperature and
concentrated under reduced pressure to give a brown residue. The
residue was puriﬁed by prep-HPLC (TFA condition) to give 5-(4-(3bromophenyl)piperazin-1-yl)pyrimidine-2,4-diamine 32 (86.5 mg,
249.6 μmol, 30.0% yield) as a white solid. LC/MS method D (ESI
+): expected m/z (349.0 and 351.1 M + 1)+; found m/z 349.0 and
351.1 (M + 1)+, tR = 2.18 min. 1H NMR (DMSO-d6, 400 MHz) δ =
7.57 (s, 1H), 7.19−7.12 (m, 1H), 7.09 (br s, 1H), 6.94 (br dd, J = 7.9,
18.4 Hz, 2H), 5.65 (s, 2H), 3.29 (br s, 4H), 2.85 (br s, 4H).
5-(4-Phenylpiperazin-1-yl)pyrimidine-2,4-diamine (7). 7 was
prepared in an analogous 3 step manner as described for 32 starting
with 1-phenylpiperazine (36b) to give a light yellow solid (26.6%
yield). 1H NMR (DMSO-d6) δ = 7.59 (s, 1H), 7.22 (br t, J = 7.8 Hz,
2H), 6.96 (br d, J = 8.2 Hz, 2H), 6.78 (t, J = 7.0 Hz, 1H), 6.07 (br s,
2H), 5.61 (br s, 2H), 3.25 (br s, 4H), 2.88 (br t, J = 4.5 Hz, 4H). LC/
MS (M + 1) expected MW 271.1, observed MW 271.1,% UV purity
99.9%.
5-(4-([1,1′-Biphenyl]-2-yl)piperazin-1-yl)pyrimidine-2,4-diamine (8). 8 was prepared in an analogous 3 step manner as described
for 32 above starting with 1-([1,1′-biphenyl]-2-yl)piperazine (36c) to
give 8 in 7.0% yield as a white solid. 1H NMR (DMSO-d6) δ = 7.65
(br d, J = 7.6 Hz, 2H), 7.48 (s, 1H), 7.44 (br t, J = 7.2 Hz, 2H), 7.31
(br t, J = 7.2 Hz, 2H), 7.21 (br d, J = 7.2 Hz, 1H), 7.12−7.05 (m,
2H), 5.99 (br s, 1H), 5.60 (s, 2H), 2.88 (br s, 4H), 2.64 (br s, 4H).
LC/MS (M + 1) expected MW 347.2, observed MW 347.2, UV
purity 97.8%.
5-(4-([1,1′-Biphenyl]-4-yl)piperazin-1-yl)pyrimidine-2,4-diamine (9). 9 was prepared in an analogous 3 step manner as described

for 32 starting with 1-([1,1′-biphenyl]-4-yl)piperazine (36d) to give 9
in 10.6% yield as a white solid. 1H NMR (methanol-d4) δ = 7.60−7.50
(m, 5H), 7.39 (br t, J = 7.4 Hz, 2H), 7.30−7.23 (m, 1H), 7.10 (br d, J
= 8.6 Hz, 2H), 3.48−3.36 (m, 4H), 3.03 (br d, J = 4.3 Hz, 4H). LC/
MS (M + 1) expected MW 347.2, observed MW 347.2, UV purity
96.7%.
5-(4-(o-Tolyl)piperazin-1-yl)pyrimidine-2,4-diamine (10). 10
was prepared in an analogous 3 step manner as described for 32
starting with 1-(o-tolyl)piperazine (36e) to give 10 in 32.8% yield as a
white solid. 1H NMR (methanol-d4) δ = 7.53 (s, 1H), 7.21−7.11 (m,
3H), 7.03−6.97 (m, 1H), 3.10 (br s, 4H), 3.03 (br d, J = 4.0 Hz, 4H),
2.34 (s, 3H). LC/MS (M + 1) expected MW 285.2, observed MW
285.1, UV purity 99.4%.
5-(4-(m-Tolyl)piperazin-1-yl)pyrimidine-2,4-diamine (11).
11 was prepared in an analogous 3 step manner as described for 32
starting with 1-(m-tolyl)piperazine (36f) to give 11 in 7.2% yield as a
yellow solid. 1H NMR (DMSO-d6) δ = 7.59 (s, 1H), 7.10 (t, J = 7.8
Hz, 1H), 6.83−6.70 (m, 2H), 6.60 (br d, J = 7.4 Hz, 1H), 6.08 (br s,
2H), 5.62 (s, 2H), 3.23 (br s, 4H), 2.86 (br t, J = 4.3 Hz, 4H), 2.25 (s,
3H). LC/MS (M + 1) expected MW 285.1, observed MW 285.1, UV
purity 99.5%.
5-(4-(p-Tolyl)piperazin-1-yl)pyrimidine-2,4-diamine (12). 12
was prepared in an analogous 3 step manner as described for 32
starting with 1-(p-tolyl)piperazine (36g) to give 12 in 2.3% yield as a
white solid. 1H NMR (DMSO-d6) δ = 7.58 (s, 1H), 7.03 (d, J = 8.4
Hz, 2H), 6.86 (d, J = 8.4 Hz, 2H), 6.06 (br. s., 1H), 5.60 (s, 2H), 3.19
(br. s., 4H), 2.87 (d, J = 4.0 Hz, 4H), 2.20 (s, 3H). LC/MS (M + 1)
expected MW 285.1, observed MW 285.1, UV purity 98.1%.
5-(4-(2-Chlorophenyl)piperazin-1-yl)pyrimidine-2,4-diamine (13). 13 was prepared in an analogous 3 step manner as
described for 32 starting with 1-(2-chlorophenyl)piperazine (36h) to
give 13 in 19.4% yield as a light yellow solid. 1H NMR (DMSO-d6) δ
= 7.62 (s, 1H), 7.42 (br d, J = 7.8 Hz, 1H), 7.35−7.28 (m, 1H), 7.18
(br d, J = 7.8 Hz, 1H), 7.05 (br t, J = 7.4 Hz, 1H), 6.09 (br s, 2H),
5.63 (s, 2H), 3.11 (br s, 4H), 2.91 (br d, J = 3.9 Hz, 4H). LC/MS (M
+ 1) expected MW 305.1, observed MW 305.1, UV purity 99.1%.
5-(4-(3-Chlorophenyl)piperazin-1-yl)pyrimidine-2,4-diamine (14). 14 was prepared in an analogous 3 step manner as
described for 32 starting with 1-(3-chlorophenyl)piperazine (36i) to
give 14 in 6.6% yield as a solid. 1H NMR (DMSO-d6) δ = 11.76 (br,
1H), 8.43 (br s, 1H), 7.65 (br s, 1H), 7.56 (br s, 1H), 7.43 (br s, 2H),
7.23 (br t, J = 8.4 Hz, 1H), 6.98 (br s, 1H), 6.93 (br d, J = 8.4 Hz,
1H), 6.80 (br d, J = 7.6 Hz, 1H), 3.36 (br s, 4H), 2.86 (br s, 4H).
LC/MS (M + 1) expected MW 305.1, observed MW 305.1, UV
purity 98.1%.
5-(4-(4-Chlorophenyl)piperazin-1-yl)pyrimidine-2,4-diamine (15). 15 was prepared in an analogous 3 step manner as
described for 32 starting with 1-(4-chlorophenyl)piperazine (36j) to
give 15 in 71.9% yield as a white solid. 1H NMR (DMSO-d6) δ = 7.58
(s, 1H), 7.24 (br d, J = 9.0 Hz, 2H), 6.97 (br d, J = 9.0 Hz, 2H), 6.08
(br s, 1H), 5.61 (s, 2H), 3.26 (br s, 4H), 2.86 (br t, J = 4.3 Hz, 4H).
LC/MS (M + 1) expected MW 305.1, observed MW 305.1, UV
purity 96.3%.
5-(4-(3-Methoxyphenyl)piperazin-1-yl)pyrimidine-2,4-diamine (16). 16 was prepared in an analogous 3 step manner as
described for 32 starting with 1-(3-methoxyphenyl)piperazine (36k)
to give 16 in 24.2% yield as a white solid. 1H NMR (DMSO-d6) δ =
7.58 (s, 1H), 7.11 (t, J = 8.4 Hz, 1H), 6.54 (br d, J = 8.0 Hz, 1H),
6.47 (s, 1H), 6.37 (br d, J = 8.0 Hz, 1H), 6.08 (br s, 1H), 5.61 (s,
2H), 3.72 (s, 3H), 3.25 (br s, 4H), 2.86 (br d, J = 4.0 Hz, 4H). LC/
MS (M + 1) expected MW 301.1, observed MW 301.1, UV purity
98.7%.
5-(4-(3-(Triﬂuoromethyl)phenyl)piperazin-1-yl)pyrimidine2,4-diamine (17). 17 was prepared in an analogous 3 step manner as
described for 32 starting with 1-(3-triﬂuoromethylphenyl)piperazine
(36l) to give 17 in 18.8% yield as a yellow solid. 1H NMR (methanold4) δ = 7.50 (s, 1H), 7.44−7.39 (m, 1H), 7.23 (br d, J = 8.8 Hz, 1H),
7.20 (br s, 1H), 7.10 (br d, J = 7.5 Hz, 1H), 3.40 (br s, 4H), 3.01 (br
d, J = 4.4 Hz, 4H). LC/MS (M + 1) expected MW 339.1, observed
MW 339.1, UV purity 99.5%.
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5-(4-(3-(Triﬂuoromethoxy)phenyl)piperazin-1-yl)pyrimidine-2,4-diamine (18). 18 was prepared in an analogous 3
step manner as described for 32 starting with 1-(3-triﬂuoromethoxyphenyl)piperazine (36m) to give 18 in 22.7% yield as a
yellow solid. 1H NMR (methanol-d4) δ = 7.49 (s, 1H), 7.31 (t, J = 8.2
Hz, 1H), 6.98 (d, J = 7.9 Hz, 1H), 6.84 (s, 1H), 6.72 (d, J = 7.9 Hz,
1H), 3.38 (s, 4H), 2.99 (s, 4H). LC/MS (M + 1) expected MW
355.1, observed MW 355.1, UV purity 100%.
5-(4-([1,1′-Biphenyl]-3-yl)piperazin-1-yl)-6-methylpyrimidine-2,4-diamine (20). 20 was prepared in an analogous 3 step
manner as described for 32 starting with 1-([1,1′-biphenyl]-3yl)piperazine (36a) and 5-bromo-6-methyluracil (34) to give 20 in
31.8% yield as a yellow solid. 1H NMR (methanol-d4) δ = 7.64−7.57
(m, 2H), 7.51−7.28 (m, 5H), 7.20 (br d, J = 7.5 Hz, 1H), 7.09 (br d,
J = 7.9 Hz, 1H), 3.66 (br d, J = 11.5 Hz, 2H), 3.45−3.35 (m, 2H),
3.26−3.16 (m, 2H), 3.03 (br d, J = 11.5 Hz, 2H), 2.38 (s, 3H). LC/
MS (M + 1) expected MW 361.2, observed MW 361.1, UV purity
95.9%.
5-(4-([1,1′-Biphenyl]-3-yl)piperazin-1-yl)-6-ethylpyrimidine2,4-diamine (21). 21 was prepared in an analogous 3 step manner as
described for 32 starting with 1-([1,1′-biphenyl]-3-yl)piperazine
(36a) and 5-bromo-6-ethyluracil (35) to give 21 in 71.4% yield as
a yellow solid. 1H NMR (methanol-d4) δ = 7.61 (d, J = 7.2 Hz, 2H),
7.43 (d, J = 8.0 Hz, 4H), 7.36 (d, J = 6.4 Hz, 1H), 7.30 (d, J = 7.2 Hz,
1H), 7.18 (d, J = 7.2 Hz, 1H), 3.65 (d, J = 9.2 Hz, 2H), 3.44−3.31
(m, 4H), 3.12 (d, J = 8.8 Hz, 2H), 2.73 (d, J = 7.6 Hz, 2H), 1.33 (t, J
= 6.8 Hz, 3H). LC/MS (M + 1) expected MW 375.2, observed MW
375.1, UV purity 98.7%.
Compounds 3, 19, 23, 24, 26, 28, 30, and 31 were prepared in a
similar fashion as described below for the synthesis of 29.
5-(4-(3-(2-Methylpyrimidin-5-yl)phenyl)piperazin-1-yl)pyrimidine-2,4-diamine (29). A mixture of 5-(4-(3-bromophenyl)piperazin-1-yl)pyrimidine-2,4-diamine 32 (1.0 g, 2.8 mmol, 1.0
equiv), (2-methylpyrimidin-5-yl)boronic acid 39u (395 mg, 2.8
mmol, 1.0 equiv), Cs2CO3 (1.4 g, 4.3 mmol, 1.5 equiv), Pd(PPh3)4
(165 mg, 143 μmol, 0.05 equiv) in dioxane (32 mL), and H2O (8.0
mL) was degassed and purged with N2 3 times and then stirred at 100
°C for 12 h under N2 atmosphere. Then it was stirred with silica S
thiol Met at 20 °C, ﬁltered, and concentrated to give a residue. The
residue was puriﬁed by prep-HPLC (TFA condition) to give 5-(4-(3(2-methylpyrimidin-5-yl)phenyl)piperazin-1-yl)pyrimidine-2,4-diamine 29 (1.2 g, 2.5 mmol, 88.0% yield) as a white solid. 1H NMR
(methanol-d4) δ = 8.93 (s, 2H), 7.51 (s, 1H), 7.41 (t, J = 7.8 Hz, 1H),
7.26−7.24 (m, 1H), 7.16−7.09 (m, 2H), 3.44 (br s, 4H), 3.02 (br t, J
= 4.8 Hz, 4H), 2.73 (s, 3H). LC/MS expected m/z 363.2 (M + 1)+;
found m/z 363.1 (M + 1)+. UV purity 99.0%.
5-(4-(3-(2-Methoxypyrimidin-5-yl)phenyl)piperazin-1-yl)pyrimidine-2,4-diamine (3). 3 was prepared in an analogous
manner as described for 29 starting with 32 and 5-(2methoxypyrimidinyl)boronic acid (39o) to give 3 in 92.8% yield as
a light yellow solid. 1H NMR (methanol-d4) δ = 8.81 (s, 2H), 7.51 (s,
1H), 7.39 (br t, J = 7.6 Hz, 1H), 7.22 (br s, 1H), 7.14−7.07 (m, 2H),
4.06 (s, 3H), 3.44 (br s, 4H), 3.03 (br s, 4H). Elemental analysis for
C19H22N8O + 0.15 H2O: theoretical C 59.83%, H 5.90%, N 29.39%.
Found C 59.56%, H 5.83%, N 29.05%. LC/MS (M + 1) expected
MW 379.2, observed MW 379.1, UV purity 96.4%.
5-(4-(3-Cyclopropylphenyl)piperazin-1-yl)pyrimidine-2,4diamine (19). 19 was prepared in an analogous manner as described
for 29 starting with 32 and cyclopropyl boronic acid (39p) to give 19
in 59.2% yield as solid. 1H NMR (methanol-d4) δ = 7.52 (br s, 1H),
7.20 (br d, J = 7.2 Hz, 1H), 6.97−6.83 (m, 2H), 6.73 (br s, 1H), 3.43
(br s, 4H), 3.06 (br s, 4H), 1.91 (br s, 1H), 0.96 (br d, J = 6.0 Hz,
2H), 0.68 (br s, 2H). LC/MS (M + 1) expected MW 311.2, observed
MW 311.1, UV purity 98.9%.
5-(4-(3-(Pyridin-3-yl)phenyl)piperazin-1-yl)pyrimidine-2,4diamine (23). 23 was prepared in an analogous manner as described
for 29 starting with 32 and 3-pyridylboronic acid (39q) to give 23 in
28.2% yield as a light yellow oil. 1H NMR (methanol-d4) δ = 9.08 (br
s, 1H), 8.79−8.69 (m, 2H), 8.01 (br s, 1H), 7.52 (s, 1H), 7.49−7.44
(m, 1H), 7.36 (s, 1H), 7.24 (d, J = 7.6 Hz, 1H), 7.19 (dd, J = 2.0, 8.4

Hz, 1H), 3.48 (br s, 4H), 3.04 (br s, 4H). LC/MS (M + 1) expected
MW 348.2, observed MW 348.2, UV purity 98.2%.
5-(4-(3-(Pyridin-4-yl)phenyl)piperazin-1-yl)pyrimidine-2,4diamine (24). 24 was prepared in an analogous manner as described
for 29 starting with 32 and 4-pyridylboronic acid (39r) to give 24 in
11.5% yield. 1H NMR (methanol-d4) δ = 8.56 (br s, 2H), 7.73−7.62
(m, 3H), 7.39 (br d, J = 8.8 Hz, 1H), 7.33 (br s, 1H), 7.22 (br d, J =
7.2 Hz, 1H), 7.13 (br d, J = 7.6 Hz, 1H), 3.50−3.35 (m, 4H), 3.03 (br
s, 4H). LC/MS (M + 1) expected MW 348.2, observed MW 348.2,
UV purity 95.3%.
5-(4-(3-(Pyrimidin-5-yl)phenyl)piperazin-1-yl)pyrimidine2,4-diamine (26). 26 was prepared in an analogous manner as
described for 29 starting with 32 and 5-pyrimidinylboronic acid (39s)
to give 26 in 34.9% yield as a light yellow oil. 1H NMR (methanol-d4)
δ = 9.14 (br s, 1H), 9.07 (br s, 2H), 7.52 (s, 1H), 7.49−7.42 (m, 1H),
7.34 (br s, 1H), 7.21 (br dd, J = 7.7, 18.7 Hz, 2H), 3.48 (br s, 4H),
3.05 (br s, 4H). LC/MS (M + 1) expected MW 349.1, observed MW
349.1, UV purity 95.8%.
5-(4-(3-(Pyridazin-4-yl)phenyl)piperazin-1-yl)pyrimidine2,4-diamine (28). 28 was prepared in an analogous manner as
described for 29 starting with 32 and 4-pyridazineboronic acid pinacol
ester (39t) to give 28 in 9.2% yield as a yellow solid. 1H NMR
(methanol-d4) δ = 9.59 (s, 1H), 9.25 (d, J = 5.3 Hz, 1H), 8.10 (dd, J =
2.4, 5.5 Hz, 1H), 7.55−7.41 (m, 3H), 7.34 (br d, J = 7.9 Hz, 1H),
7.22 (br d, J = 8.4 Hz, 1H), 3.48 (br s, 4H), 3.04 (br d, J = 4.4 Hz,
4H). LC/MS (M + 1) expected MW 349.2, observed MW 349.1, UV
purity 100%.
5-(4-(3-(2-(Triﬂuoromethyl)pyrimidin-5-yl)phenyl)piperazin-1-yl)pyrimidine-2,4-diamine (30). 30 was prepared in
an analogous manner as described for 29 starting with 32 and 5-(2triﬂuoromethylpyrimidine)boronic acid (39v) to give 30 in 27.3%
yield as a yellow solid. 1H NMR (methanol-d4) δ = 9.23 (s, 2H), 7.51
(s, 1H), 7.46−7.44 (m, 1H), 7.36 (s, 1H), 7.25 (d, J = 8.0 Hz, 1H),
7.18 (d, J = 6.4 Hz, 1H), 3.47 (br s, 4H), 3.03 (br s, 4H). LC/MS (M
+ 1) expected MW 417.2, observed MW 417.1, UV purity 98.2%.
5-(4-(3-(2-Cyclopropylpyrimidin-5-yl)phenyl)piperazin-1yl)pyrimidine-2,4-diamine (31). 31 was prepared in an analogous
manner as described for 29 starting with 32 and 5-(2-cyclopropylpyrimidine)boronic acid (39w) to give 31 in 42.9% yield as a light
yellow solid. 1H NMR (methanol-d4) δ = 8.89 (s, 2H), 7.52 (s, 1H),
7.43−7.41 (m, 1H), 7.28 (s, 1H), 7.19−7.13 (m, 2H), 3.46 (br s,
4H), 3.04 (br s, 4H), 2.30−2.25 (m, 1H), 1.17−1.15 (m, 4H).
Expected MW 389.2, observed MW 389.1, UV purity 100%.
Compounds 25 and 27 were prepared in a fashion as described
below for the synthesis of 22.
5-(4-(3-(Pyridin-2-yl)phenyl)piperazin-1-yl)pyrimidine-2,4diamine (22). A mixture of 5-(4-(3-bromophenyl)piperazin-1yl)pyrimidine-2,4-diamine 32 (100.0 mg, 286.3 μmol, 1.0 equiv),
tributyl(pyridin-2-yl)stannane 40x (106 mg, 286 μmol, 1 equiv),
Pd2(dba)3 (7.8 mg, 8.6 μmol, 0.03 equiv), XPhos (23 mg, 49 μmol,
0.17 equiv) in dioxane (8.0 mL) was degassed and purged with N2 3
times. The mixture was stirred at 100 °C for 12 h under N2
atmosphere, concentrated under reduced pressure and the residue
was puriﬁed by prep-HPLC (TFA condition) to give 5-(4-(3(pyridin-2-yl)phenyl)piperazin-1-yl)pyrimidine-2,4-diamine 22 (4.5
mg, 4.5% yield) as a yellow solid. LC/MS method D (ESI+):
expected m/z (348.2 M + 1)+; found m/z 348.1 (M + 1)+. 1H NMR
(CD3OD-d6) δ = 8.60 (br d, J = 4.9 Hz, 1H), 7.94−7.88 (m, 1H),
7.87−7.82 (m, 1H), 7.63 (s, 1H), 7.58 (s, 1H), 7.42−7.34 (m, 3H),
7.12 (br s, 1H), 3.39 (br d, J = 11.0 Hz, 4H), 3.03 (br t, J = 4.6 Hz,
4H).
5-(4-(3-(Pyrimidin-2-yl)phenyl)piperazin-1-yl)pyrimidine2,4-diamine (25). 25 was prepared in an analogous manner as
described for 22 starting with 32 and tributyl(pyrimidin-2-yl)stannane
(40y) to give 25 in 23.5% yield as a white solid. 1H NMR
((methanol-d4) δ = 8.85 (br s, 2H), 8.07 (br s, 1H), 7.92 (br d, J = 6.6
Hz, 1H), 7.52 (br s, 1H), 7.40 (br d, J = 13.7 Hz, 2H), 7.21 (br s,
1H), 3.46 (br s, 4H), 3.05 (br s, 4H). expected MW 349.2, observed
MW 349.2, UV purity 97.1%.
5-(4-(3-(Pyrazin-2-yl)phenyl)piperazin-1-yl)pyrimidine-2,4diamine (27). 27 was prepared in an analogous manner as described
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300g for 5 min at room temperature and then incubated at 37 °C in
5% CO2 for 72 h. At the end of the incubation period, the monolayer
was lysed in 1% Triton X-100 and β-gal activity monitored using 1
mM chlorophenol red β-D-galactopyranoside by absorption at 570
nm, as described previously. 56 Individual EC50 values were
determined from three or more independent biological replicates
and are reported as mean values.
Generation of Fireﬂy Luciferase (FLUC) Tagged Strains. This
work was performed at Washington University of St. Louis, MO.
Experiments were conducted with the ME49Δhx::FLUC strain of T.
gondii, a transgenic line that expresses ﬁreﬂy luciferase (FLUC).57 To
tag additional strains with FLUC, a reporter plasmid was created
using a two-step Gibson assembly approach. Fragment 1 was
generated from PCR linearized pUPRT::Floxed DHFR-TS* plasmid
(Addgene no. 100606) that includes both 5′ and 3′ uracil
phosphoribosyltransferase (UPRT) ﬂanking regions to drive locus
speciﬁc integration at the UPRT gene and a ﬂoxed T. gondii DHFR
selectable marker. Fragment 2 was synthesized using a gBlock (IDT
DNA) containing the constitutive T. gondii α-tubulin promoter (608bp) driving expression of the ﬁreﬂy luciferase reporter (1641-bp). The
expression construct was targeted to the UPRT gene in T. gondii by
co-transfection with the CRISPR plasmid pSAG1:CAS9, U6:sgUPRT.
Parasites were sequentially selected in pyrimethamine (1.0 μM)
followed by 5-ﬂuorodeoxyracil (FUDR, 10 μM) and independent
clones isolated by limiting dilution. All clones contain the ﬂoxed
T.gondii DHFR selectable marker that can be excised using a plasmid
expressing CRE recombinase.
In Vitro Growth Assays Using Luciferase. To assess potency of
compounds on diﬀerent strains of T. gondii, values were determined
from a 10-point dose−response curve. Brieﬂy, 5 × 103 of luciferase
expressing parasites (100 μL/well) were added to a 96-well plate that
contained 100 μL of 2× compound concentration (to achieve 1× ﬁnal
compound concentration in 200 μL total well volume containing 0.1%
DMSO) and allowed to replicate for 72 h prior to preparation for
luciferase assay. All experimental steps, growth conditions, and
luciferase assay protocols were completed as described above.
Compounds were tested using a 3-fold dilution series from 10 μM
to 0.001 μM with all wells containing a ﬁnal concentration of 0.1%
DMSO. The EC50 data are presented as the average of three or more
biological replicates (i.e., separate EC50 titrations) each with two
technical replicates (i.e., separate wells).
Antiproliferative Assay in MCF7 Cells. This work was
performed at Cyprotex in Watertown, MA. MCF-7 cells were plated
on 96-well tissue culture treated polystyrene plates at 0.75 × 104 cells
in 100 μL of MEM/EBSS (supplemented with 10% fetal bovine
serum, sodium pyruvate, and antibiotics) per well. After an overnight
incubation at 37 °C, the cells were dosed with test compounds and
controls at a range of concentrations and incubated for 72 h at 37 °C.
Pyrimethamine 1 was tested from 0.156 to 20 μM, and compound 3
was evaluated from 0.313 to 40 μM with an 8-point dose curve in
triplicate on three separate plates. Cell viability was measured using
the Promega CellTiter 96 nonradioactive cell proliferation assay
(MTT) kit by adding 15 μL of the dye solution to each well and
incubating for 3 h at 37 °C. After incubation, 100 μL of the
solubilization solution/stop mix was added to each well. Plates were
incubated at 37 °C for 1 h, mixed on a plate shaker for 10 min, and
then absorbance was read at 570 nm. The EC50 was then calculated.
Pharmacokinetics (Mouse). Fasted female CD-1 mice (n = 3),
6−8 weeks old (supplied from Beijing Vital River Laboratory Animal
Technology Co., Ltd.) were administered a 0.5 mg/kg intravenous
dose of compound 3, formulated as a clear 0.1 mg/mL solution in
saline at pH 5. A second group (n = 3) was administered a 0.83 mg/
kg oral dose of compound 3 (targeted dose was 1.0 mg/kg),
formulated as a 0.1 mg/mL homogeneous opaque suspension with
ﬁne particles in 0.5% CMC. Plasma (EDTA-K2) from the iv dose was
collected at 0.083, 0.50, 1.0, 2.0, 4.0, 8.0, and 24 h. Plasma (EDTAK2) from the po dose was collected at 0.50, 1.0, 2.0, 4.0, 8.0, 12, and
24 h. Plasma preparation: An aliquot of 10 μL plasma was protein
precipitated with 100 μL of IS, and the mixture was vortexed and
centrifuged at 13 000 rpm for 10 min, 4 °C. The supernatant (25 μL)

for 22 starting with 32 and tributyl(pyrazin-2-yl)stannane (40z) to
give 27 in 50.1% yield as a light yellow solid. 1H NMR (methanol-d4)
δ = 9.19 (s, 1H), 8.73 (s, 1H), 8.60 (br d, J = 2.0 Hz, 1H), 8.30 (s,
1H), 8.11 (br d, J = 7.6 Hz, 1H), 7.73−7.65 (m, 2H), 7.62 (s, 1H),
3.85 (br s, 4H), 3.30−3.26 (m, 4H). expected MW 349.2, observed
MW 349.2, UV purity 99.1%.
DHFR Assay for Human and T. gondii. All compounds were
tested in duplicate and replicated in at least 3 independent
experiments. Human and T. gondii DHFR assays were run in parallel
using the same stocks to optimize selectivity data. Key comparator
compounds 1 (n = 12 for human and T. gondii) and 3 (n = 16 for
human and T. gondii) were tested in free base form on the same days
for optimal comparison. The protein expression and puriﬁcation
protocol were adapted from a previously published procedure.29 T.
gondii TS-DHFR was subcloned into a PET15b plasmid and
transformed into Escherichia coli BL21 competent cells. Overnight
cultured bacteria were inoculated into a 1 L of LB culture media at a
ratio of 1:100 at 37 °C. Upon reaching a q.d. 600 nm of 0.7, protein
expression was induced with 0.5 mM isopropyl β-D-thiogalactoside at
16 °C overnight. Cells were then pelleted (∼4.6 g) and resuspended
in buﬀer A (25 mM Tris-HCl, pH 7.3, 100 mM NaCl, 1 mM EDTA)
before lysis by sonication. MTX agarose beads (∼1 mL) were added
to the lysate, and the beads were subsequently washed 2× with buﬀer
A (∼10 mL) and 1× with buﬀer B (∼10 mL, 25 mM Tris-HCl, pH
7.3, 1 M KCl, 1 mM EDTA) prior to elution with buﬀer C (∼6 mL,
25 mM Tris-HCl, 10 mM DTT, 10% glycerol, 2 mM H2F). The
eluent containing the puriﬁed enzyme was then concentrated and the
protein was transferred, using a PD-MiniTrap G-25 column, to the
ﬁnal storage buﬀer (25 mM Tris-HCl, 10 mM DTT, 10% glycerol).
Puriﬁed hDHFR was obtained commercially from Sigma-Aldrich,
dihydrofolate reductase human (Sigma D6566). The protein was
conﬁrmed by sequencing.
The diaphorase-coupled assay for DHFR activity was adapted from
a previously published procedure.55 Compounds were added as
solutions of DMSO at 100× the desired concentration to puriﬁed
enzyme (1 μg/mL) suspended in assay buﬀer (150 mM KCl, 8.9 mM
β-mercaptoethanol in 40.0 mM sodium phosphate at pH 7.4) in 384well format (Corning 3573). Following a 15 min incubation at 25 °C,
solutions of NADPH (1.6 μM, Sigma N7505) and DHF (10 μM,
Sigma D7006) in assay buﬀer were added sequentially. The plate was
then incubated at 25 °C for an additional 60 min prior to the addition
of diaphorase (10 U/mL) and resazurin (5 μM, Sigma R7017). After
a ﬁnal 10 min incubation at 25 °C, ﬂuorescence was measured using
an EnVision plate reader (531 nm Ex/590 nm Em). IC50 values were
determined from the raw ﬂuorometric data by nonlinear regression
using GraphPad Prism.
Parasite Strains and Cell Lines. Tachyzoites of T. gondii strains
were grown in monolayers of human foreskin ﬁbroblasts (HFF)
(ATCC SCRC 1041) maintained in complete medium (DMEM
containing 10% FBS, 2 mM L-glutamine, 10 mM HEPES, and 10 μg/
mL gentamicin in 35 mM NaHCO3 solution), 37 °C in 5% CO2.
Following natural egress, tachyzoites were puriﬁed in HBSS
containing 10 mM HEPES, 0.1 mM EGTA and separated from
host debris using 3.0 micro polycarbonate membrane ﬁlters, followed
by centrifugation at 400g.
Cell-Based Parasite Growth Assays Using β-Galactosidase.
This work was performed at Evotec in Manchester, U.K. Parasite
growth inhibition assays were conducted using the type I RH strain,
2F clone that expresses bacterial β-galactosidase (β-gal), as described
previously.56 Compounds dissolved in DMSO at 10 mM stocks were
diluted in medium to 2 times ﬁnal concentrations and added to an
equal volume of medium containing 5 × 102 parasites and incubated
for 20 min. Mixtures of compounds (ranging from 10 μM to 0.01
nM) containing 0.1% (v/v) DMSO or DMSO alone was added to
monolayers of HFF cells grown in 96-well plates, centrifuged at 300g
for 5 min, and returned to culture at 37 °C, 5% CO2. The cells were
preincubated for 2 h in the presence of parasites. Varying
concentrations of drugs were added to each well (100 μL volumes
containing 0.2% DMSO in D10 media) to give a ﬁnal concentration
range of 0.02−10 μM in 0.1% DMSO. The plates were centrifuged at
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was then mixed with 25 μL of water/ACN (v:v, 95:5) containing 0.1%
formic acid, vortexed, and centrifuged at 4 °C. 3 μL of supernatant
was injected for LC−MS/MS analysis. Concentration of compound 3
was determined using an LC−MS/MS-AG (API 4000) instrument in
ESI positive mode with SRM detection monitoring for [M + H]+ m/z
transition 379.3/152.2 and using an internal standard 100 ng/mL
tolbutamide [M + H]+ m/z transition 271.1/155.1. The UPLC
method mobile phase Aof 0.025% formic acid, 1 mM NH4OAc in
water/ACN (v:v, 95:5) and mobile phase B of 0.025% formic acid, 1
mM NH4OAc in ACN/water (v:v, 95:5) used a gradient starting with
15% mobile phase B and going to 90% over 1.40 min, on a Acquity
UPLC BEH C18 1.7 μm, 2.1 mm × 50 mm column at 60 °C at a ﬂow
rate of 0.7 mL/min. The retention time of compound 3 was 0.55 min
and tolbutamide 0.88 min. A calibration curve from 1.00 to 3000 ng/
mL of compound 3 in male CD-1 mouse plasma (EDTA-K2) was
made, and the data were analyzed using Phoenix WinNonlin 6.3 with
a linear/log trapezoidal calculation method.
Brain to Blood Ratio (Mouse). This work was performed at
Evotec, Manchester, U.K. Fed female CD1 mice (n = 3) were orally
administered 10 mg/kg of the TFA-salt form of compound 3,
formulated as a clear solution in 0.25% carboxymethyl cellulose
(CMC). Blood (EDTA-K2) 20 μL was collected by tail prick of the
lateral tail vein 0.5 h postdose and diluted 2× with water for LC−MS/
MS injection. Animals were then euthanized, and brain was collected
and homogenized. The brain homogenates (40 μL) were run within
the blood calibration curve and utilized the homogenization dilution
factors for ﬁnal quantitation but also incorporated a 2-fold adjustment
for sample volume versus blood.
In Vivo Murine Model of Toxoplasmosis. This work was
performed at Evotec in Manchester, U.K. Fed female CD-1 mice (60
mice per study; 12 mice per drug treatment group, 9 mice for vehicle
and 3 mice as negative controls) were inoculated intraperitoneally
with 3000 tachyzoites of the highly virulent RH strain of T. gondii on
day 0. The T. gondii strain used in this study had been genetically
modiﬁed to constitutively express the enzyme ﬁre ﬂy luciferase
(FLUC) and enable infection monitoring via an in vivo bioluminescence imaging system.51 Beginning 24 h after inoculation,
mice were dosed with either compound 1 formulated at 0.6, 1.8, and
5.4 mg/mL in 0.25% CMC or the TFA salt form of compound 3
formulated in 0.25% CMC at 0.1 mg/mL, 0.3 mg/mL, or 1.0 mg/mL
as a clear solution and dosed at a volume of 10 mL/kg. On day 4
microsampling of blood from the tail vein was collected into K2EDTA
tubes and evaluated by LC/MS−MS as described above for the
mouse brain to blood experiment.
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